Sage Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Sage Therapeutics's estimated annual revenue is currently $97.7M per year.
- Sage Therapeutics received $575.0M in venture funding in February 2018.
- Sage Therapeutics's estimated revenue per employee is $127,148
- Sage Therapeutics's total funding is $1.1B.
Employee Data
- Sage Therapeutics has 768 Employees.
- Sage Therapeutics grew their employee count by 4% last year.
Sage Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP | Reveal Email/Phone |
2 | Executive Director, Accounting | Reveal Email/Phone |
3 | SVP Regulatory Affairs | Reveal Email/Phone |
4 | SVP, Global Medical Affairs | Reveal Email/Phone |
5 | VP, Market Access Field and Field Sales | Reveal Email/Phone |
6 | Head US Commercial Compliance, Collaboration Compliance, & Compliance Ops (Exec. Director) | Reveal Email/Phone |
7 | Director- Global Commercial Business Management, Chief Staff | Reveal Email/Phone |
8 | SVP, External Affairs | Reveal Email/Phone |
9 | VP Regulatory Affairs | Reveal Email/Phone |
10 | VP Biostatistics, Programming, Modeling & Simulation | Reveal Email/Phone |
Sage Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Sage Therapeutics?
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage's lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$1.1B
Total Funding
768
Number of Employees
$97.7M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sage Therapeutics News
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health,...
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Recommendation of Hold from Brokerages. Posted by admin on Apr 18th, 2022.
Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with better brain health. Our mission is to...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 17, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported complete 12-month data from the 30 mg cohort and interim data from the 50 mg cohort of the ongoing Phase 3 open-label SHORELINE Study. This clinical study was designed to naturalistically fol ...
On December 31, 2020, Sage Therapeutics, Inc. (NasdaqGM:SAGE) closed the transaction. The company raised $649,986,998 pursuant to Regulation D.
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $159.7M | 770 | 11% | N/A |
#2 | $151.1M | 771 | 10% | N/A |
#3 | $382.5M | 774 | 8% | N/A |
#4 | $75M | 819 | 9% | N/A |
#5 | $170.6M | 823 | -11% | $90M |
Sage Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-10-17 | $20.0M | B | ARCH Venture Partners | Article |
| 2014-01-23 | $10.0M | Undisclosed | Article | |
| 2014-03-14 | $38.0M | C | Multiple | Article |
| 2015-04-15 | $115.0M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2015-04-22 | $138.0M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2017-11-15 | $345.0M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2018-02-09 | $575.0M | Undisclosed | J.P. Morgan Securities LLC | Article |